To Create The 340b Program Transparency Act; And To Amend The Law Concerning Transparency And Accountability For Certain 340b-covered Entities.
SB589 creates the “340B Program Transparency Act” and applies it to Arkansas hospitals and other in-state healthcare providers that participate in the federal 340B drug discount program. The bill requires each covered entity to file an annual report with the Department of Health by March 31 covering the prior calendar year. The report must disclose estimated 340B savings, the methodology used to calculate those savings, the number of claims processed, and detailed information about how the savings were used.
The required disclosures are broad and include spending on uncompensated or charity care, patient financial assistance, access-expansion efforts in medically underserved areas, administrative costs, affiliated foundations or charities, contract pharmacy arrangements, and other itemized uses of savings. The bill also requires reporting of charity care and bad debt metrics, patient counts by county, the number of clinics or facilities in medically underserved areas, and contract pharmacy claim volumes. The Department of Health must post the reports publicly, subject to redaction of protected trade secrets or proprietary information, and may adopt rules, review reports, and conduct audits or investigations.
SB589 would add a new subchapter to Arkansas Code Title 20, Chapter 6, establishing state-level reporting and oversight requirements for 340B-covered entities. It would not change the federal 340B program itself, but it would require Arkansas participants to document and disclose how they calculate and spend 340B savings, and it would authorize the Department of Health to enforce compliance through audits and administrative penalties of up to $500 per day, capped at $150,000 per year. The act would take effect January 1, 2026.
No committee transcripts or recorded votes were provided, so there is no direct evidence of legislative debate or formal support/opposition in the available materials. Based on the bill text alone, the measure appears to be framed as an accountability and transparency bill, suggesting a policy goal of public reporting rather than program expansion or reduction. The absence of voting history or hearing discussion makes the overall sentiment difficult to gauge beyond the bill’s stated emphasis on transparency.
The main likely points of contention are the scope and burden of the reporting requirements, the public disclosure of financial and operational data, and the Department of Health’s enforcement authority. Covered entities may object to the detailed accounting of savings, the county-level patient reporting, and the disclosure of contract pharmacy information, especially where proprietary or competitively sensitive information is involved. Another potential issue is the bill’s treatment of what counts as 340B savings and how savings are attributed to charity care, administrative costs, and other uses, which could raise disputes over methodology and compliance.